異位性皮膚炎：KOL 見解

Atopic Dermatitis - KOL Insight

出版日期: 年間契約型資訊服務 | 出版商:

FirstWord Group | 英文

價格

簡介目錄

本報告調查了異位性皮膚炎治療藥物的最新趨勢。根據一線 KOL 的見解，Lilly/Almirall 的 Ebglyss 預計將具有與 Dupixent 相當的功效和市場佔有率。專家們也討論了對 rocatinlimab（Kyowa Kirin/Amgen）的謹慎樂觀態度，指出需要進一步進行療效測試和副作用調查。此外，amlitelimab（Sanofi）已經顯示出有趣的 IIb 期資料和有利的給藥方案，儘管還需要更多資料。本報告目的是加深對塑造異位性皮膚炎治療未來的新生物製劑和新興療法的了解。

除了完整報告外，授權使用者還可以透過附件存取以下 KOL 公告和特別報告：

本報告回答的關鍵問題：

Dupixent（Dupilumab；Sanofi/Regeneron）如何用於治療異位性皮膚炎？進行哪些其他測試？未來將如何規定？
最近推出的產品中最有前景的作用機制和產品是什麼？
哪些管道產品最有前途？它們將如何影響當前的市場參與者？
哪些臨床試驗可能會影響處方趨勢？另外，該結果對未來異位性皮膚炎的治療有何影響？
未來異位性皮膚炎的治療現況將如何改變？

本報告調查的主要品牌

Dupixent (dupilumab)
Adbry/Adtralza (tralokinumab)
Ebglyss (lebrikizumab)
Olumiant (baricitinib)
Cibinqo (abrocitinib)

Rinvoq (upadacitinib)
nemolizumab
Velsipity (etrasimod)
rocatinlimab
amlitelimab

上市公司

AbbVie
Amgen
Lilly
Regeneron
Sanofi
Pfizer
Almirall S.A.

Leo Pharma
Incyte
Chugai
Galderma
Maruho
Kyowa Kirin

出於安全考慮，KOL 不認為 SYK/JAK 雙重抑制可有效治療異位性皮膚炎
- PD1 促效劑抗體被認為是高風險前景
- 大多數專家不認為 TYK2 抑制對異位性皮膚炎有效
- 雙特異性抗體開發前景樂觀
- 生物標記通常被認為是無關緊要的
- 減少給藥頻率在未來將變得越來越重要

附錄

KOL（關鍵意見領袖）詳細
- 美國的 KOL
- 歐洲的 KOL

簡介目錄

Explore the evolving landscape of atopic dermatitis treatment. Insights from leading KOLs highlight the promising potential of Lilly/Almirall's Ebglyss, which is expected to rival Dupixent in efficacy and market share. Experts also discuss the cautious optimism surrounding rocatinlimab (Kyowa Kirin/Amgen), noting the need for further efficacy validation and investigation into side effects. Additionally, amlitelimab (Sanofi) shows intriguing Phase IIb data with a favourable dosing schedule, though more data is required. Gain an understanding of the new biologics and emerging therapies shaping the future of atopic dermatitis treatment.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key questions answered:

How is Dupixent (dupilumab; Sanofi/Regeneron) used in the treatment of atopic dermatitis, what other trials are being conducted, and how will it be prescribed in the future?
Among recently launched products, which mechanisms of action and/or products are the most promising?
Which pipeline products are the most promising, and how will they impact current players in the market?
Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of atopic dermatitis?
How will the treatment landscape for atopic dermatitis evolve in the future?

Key brands covered in this report:

Dupixent (dupilumab)
Adbry/Adtralza (tralokinumab)
Ebglyss (lebrikizumab)
Olumiant (baricitinib)
Cibinqo (abrocitinib)

Rinvoq (upadacitinib)
nemolizumab
Velsipity (etrasimod)
rocatinlimab
amlitelimab

Companies Listed:

AbbVie
Amgen
Lilly
Regeneron
Sanofi
Pfizer
Almirall S.A.

Leo Pharma
Incyte
Chugai
Galderma
Maruho
Kyowa Kirin

Executive summary

Future treatment paradigm for atopic dermatitis

Research objectives

Current treatment strategies

Dupixent (dupilumab; Sanofi/Regeneron)
- Key insights summary
Adbry/Adtralza (tralokinumab; LEO Pharma)
- Key insights summary
Ebglyss (lebrikizumab; Lilly/Almirall)
- Key insights summary
Olumiant (baricitinib; Lilly/Incyte)
- Key insights summary
Cibinqo (abrocitinib; Pfizer)
- Key insights summary
Rinvoq (upadacitinib; AbbVie)
- Key insights summary

Late-stage pipeline programmes

Nemolizumab (Galderma/Chugai/Maruho)
- Key insights summary
Velsipity (etrasimod; Pfizer)
- Key insights summary
Rocatinlimab (Kyowa Kirin/Amgen)
- Key insights summary
Amlitelimab (Sanofi)
- Key insights summary

Earlier-stage developments and other factors impacting treatment

KOLs are unconvinced that dual SYK/JAK inhibition will have a place in atopic dermatitis due to safety concerns
- PD1 agonist antibody is deemed to be a risky prospect
- Most experts don't think TYK2 inhibition will work as well in atopic dermatitis
- Optimism surrounds the development of bispecific antibodies
- Biomarkers are generally seen as irrelevant
- Less frequent dosing will become increasingly important in the future